Trinity Capital committed $40 million in term loans to Taysha Gene Therapies, a clinical-stage gene therapy company, pursuant to a loan and security agreement dated Nov. 13, 2023 by and among Taysha, the lenders party thereto and Trinity as administrative agent and collateral agent for the lenders.
Taysha is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is in evaluation for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that treat the root cause of the disease. The company’s management team has experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and its intrathecal delivery in combination with a clinically and commercially proven AAV9 capsid in an effort to translate treatments from bench to bedside.
“We are excited to partner with Taysha as it advances its lead gene therapy program in clinical evaluation for Rett syndrome, and believe Taysha has the potential to achieve significant advancements in the gene therapy field,” Igor DaCruz, managing director of life sciences at Trinity Capital, said. “We look forward to working together with their management team as Taysha focuses on bringing novel treatments with disease-modifying potential for diseases, like Rett syndrome, with high unmet need.”
With the term loan, Taysha believes it will be able to fund its operating expenses and capital requirements into 2026 to support the clinical development of its TSHA-102 program for Rett syndrome.
“We are highly encouraged by the support from Trinity, which we believe further reinforces Taysha’s vision to transform the lives of patients suffering from devastating diseases through the development of AAV-based gene therapies,” Kamran Alam, CFO of Taysha, said. “With Trinity’s support, we believe we are well-positioned to continue to execute across our near-term milestones for our TSHA-102 program in Rett syndrome.”
